Chemotherapy and immunotherapy in metastatic colorectal cancer. Pohlmann PR, Mernaugh RL, Goff LW (2009) N Engl J Med 360: 2134; author reply 2135-6 Beyond exon 2--the developing story of RAS mutations in colorectal cancer. Berlin J (2013) N Engl J Med 369: 1059-60 Therapeutic strategies for metastatic colorectal cancer: simultaneous, sequential, or specific? Rothenberg ML, Berlin JD (2003) J Clin Oncol 21: 3716-7 Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, Alberts S, O'Dwyer P, Haller D, Catalano P, Cella D, Benson AB (2009) J Clin Oncol 27: 3778-85 Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG (2003) J Clin Oncol 21: 2059-69 Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, Kim MP, Abbruzzese JL, Ellis LM, Chandra J, Gallick GE (2009) Cancer Res 69: 3842-9 Aflibercept. Ciombor KK, Berlin J, Chan E (2013) Clin Cancer Res 19: 1920-5 A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. Berlin J, Bendell JC, Hart LL, Firdaus I, Gore I, Hermann RC, Mulcahy MF, Zalupski MM, Mackey HM, Yauch RL, Graham RA, Bray GL, Low JA (2013) Clin Cancer Res 19: 258-67 Phase 2 trial of oxaliplatin and pemetrexed as an induction regimen in locally advanced head and neck cancer. Gilbert J, Murphy B, Dietrich MS, Henry E, Jordan R, Counsell A, Wirth P, Yarbrough WG, Slebos RJ, Chung CH (2012) Cancer 118: 1007-13 Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Hecht JR, Patnaik A, Berlin J, Venook A, Malik I, Tchekmedyian S, Navale L, Amado RG, Meropol NJ (2007) Cancer 110: 980-8 Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Wheeler HE, Gamazon ER, Stark AL, O'Donnell PH, Gorsic LK, Huang RS, Cox NJ, Dolan ME (2013) Pharmacogenomics J 13: 35-43 Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells. Bose D, Zimmerman LJ, Pierobon M, Petricoin E, Tozzi F, Parikh A, Fan F, Dallas N, Xia L, Gaur P, Samuel S, Liebler DC, Ellis LM (2011) Br J Cancer 105: 1759-67 Update on new drugs in small cell lung cancer. Horn L, Castellanos EL, Johnson DH (2011) Expert Opin Investig Drugs 20: 441-5 Radiopotentiation by the oral platinum agent, JM216: role of repair inhibition. Amorino GP, Freeman ML, Carbone DP, Lebwohl DE, Choy H (1999) Int J Radiat Oncol Biol Phys 44: 399-405 Synthesis and catalytic properties of soluble platinum nanoparticles protected by a thiol monolayer. Eklund SE, Cliffel DE (2004) Langmuir 20: 6012-8 Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement. Bartlett DL, Berlin J, Lauwers GY, Messersmith WA, Petrelli NJ, Venook AP (2006) Ann Surg Oncol 13: 1284-92 Phase I trial of pemetrexed plus oxaliplatin administered every other week in patients with metastatic cancer. Stover DG, Lockhart AC, Berlin JD, Chan E, Sandler AB, Sosman JA, Middlebrook V, Nicol S, Rothenberg ML (2008) Invest New Drugs 26: 339-45 Advances in understanding drug-induced neuropathies. Peltier AC, Russell JW (2006) Drug Saf 29: 23-30 Second-line therapy in colorectal cancer. Berlin J (2000) Oncology (Williston Park) 14: 21-6 Conjugates of cisplatin and cyclooxygenase inhibitors as potent antitumor agents overcoming cisplatin resistance. Neumann W, Crews BC, Marnett LJ, Hey-Hawkins E (2014) ChemMedChem 9: 1150-3 Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer. Merchan JR, Ferrell A, Macintyre J, Ciombor KK, Levi J, Ribeiro A, Sleeman D, Flores A, Lopes G, Rocha-Lima CM (2012) Am J Clin Oncol 35: 446-50
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.